High dose intravenous immunoglobulin repertoire versus anti-D. Disproportions in quantity and quality.
Here we consider certain therapeutic effects that intravenous administration of pooled high dose immunoglobulin and anti-D IgG share. Despite million-fold difference in doses such an effect occurs at least in idiopathic thrombocytopenic purpura (ITP). We postulate that spontaneous bleeding events may remit even when platelet numbers show refractoriness. We also mention the possible sparing of anti-D antibody-coated red blood cell (RBC) destruction and, finally, an acceleration of fibrotic involution. Fc receptors (FcRs) play a central role; beyond the well-established interactions with the immunoglobulin Fc fragment, FcRs are supposed to display special cognitive properties that enable them to pick out the therapeutic molecules from the recipient's IgG pool. Such subtle selection suggests some disarray in the host. On the other hand it may explain why the often-encouraging outcome of IVIG therapy remains unpredictable.
Rewald
E
E
fuhemat@mdp.edu.ar
Francischetti
M M
MM
Barberis
L
L
D002921:Cicatrix / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology*; D007518:Isoantibodies / Q000008:administration & dosage*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy*; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin
D016756:Immunoglobulins, Intravenous; D007518:Isoantibodies; C061961:RHO(D) antibody; D012204:Rh-Hr Blood-Group System; D018029:Rho(D) Immune Globulin